Selisistat
- Generic Name
- Selisistat
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13ClN2O
- CAS Number
- 49843-98-3
- Unique Ingredient Identifier
- L19ECD5014
- Background
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Escalating Dose Study in Healthy Volunteers With SEN0014196
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- Siena Biotech S.p.A.
- Target Recruit Count
- 88
- Registration Number
- NCT01521832
- Locations
- 🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom
A Phase II Safety and Tolerability Study With SEN0014196
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Siena Biotech S.p.A.
- Target Recruit Count
- 144
- Registration Number
- NCT01521585
- Locations
- 🇩🇪
Dept. of Neurology, University of Münster, Münster, Germany
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2013-03-20
- Lead Sponsor
- Siena Biotech S.p.A.
- Target Recruit Count
- 26
- Registration Number
- NCT01485965
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
🇺🇸University of Rochester, Rocherster, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath